Intra-Cellular Therapies' GAAP loss for 6M 2021 was $121.484 million, up 9.3% from $111.123 million in the prior year. Revenue increased 12-fold to $35.925 million from $2.99 million a year earlier.
Intra-Cellular Therapies' GAAP loss for 6M 2021 was $121.484 million, up 9.3% from $111.123 million in the prior year. Revenue increased 12-fold to $35.925 million from $2.99 million a year earlier. 
ir.intracellulartherapies.com
English (US) 